Eisai is a R&D company that seeks innovative solutions in disease prevention, treatment, and care in Neurology and Oncolgy. Dayvigo is the first Orexin receptor antagonist indicated for the treatment of Insomnia in Canada with over 3.5 million patients worldwide.